This research study is looking at how imatinib affects how dasatinib is absorbed and
eliminated from the body. Both imatinib and dasatinib are in a class of medications called
tyrosine kinase inhibitors (TKI) and they are used to treat certain types of leukemia (cancer
that begins in the white blood cells). Both imatinib and dasatinib have been given safely in
healthy volunteers. In this study investigators will evaluate the pharmacokinetics
interaction between imatinib and dasatinib when they are co-administered. The hypothesis is
that imatinib will increase the blood levels of dasatinib through inhibiting the drug
metabolizing enzyme and efflux transporter that are involved in the dasatinib absorption and
removal. This research will provide important new insight of combination TKI therapy in terms
of transporter- and enzyme- mediated pharmacokinetic interactions. The research results will
also help guide doctors in knowing how much of a tyrosine kinase inhibitor to give safely
while reaching best effect in TKI combination therapy.